Time to Get Off the Elite Pharmaceuticals Train (ELTP)

Exactly one month ago today I penned some bullish thoughts on Elite Pharmaceuticals Inc. (OTCBB:ELTP). If you're familiar with the company - or a regular reader of this site - then you may know why that sounds a little "off." See, at the time, ELTP shares were falling rather quickly, giving up all the gains they had made just a few days before. Almost needless to say, my premise was not a well received one. Let's just say I received some "colorful disagreements" by being optimistic about the biopharma company.

Well, what else can I say now, other than it's fun to be right, and satisfying to be vindicated. ELTP shares have rallied 98% since my last look at the stock back on August 19th.

I'm not reprising that write-up to brag, however. I can and do misfire as much as anybody else. The reason I'm bringing Elite Pharmaceuticals up again today is to suggest now's the time to lock in your gain and walk away, if you stepped into a position on my advice last month. [Never let it be said I don't follow up on my picks.]

That's going to be about as tough to swallow for some traders as my original bullish call on ELTP was back in mid-August. Shares seem to be soaring now, and bailing out here feels like you're getting off the bullish train in the middle of the journey. I get that. I'm just saying, after too many years in this business and too many gray hairs by being in this industry, I've seen stocks get up-ended - with little to no warning - right in the middle of what seemed like an unstoppable rally. Indeed, a lot of folks were chastising me for going long on a stock that "had no shot at any upside" a month ago, yet that very stock has nearly doubled in the meantime. Nothing lasts forever, and the time to expect it is when you least expect it. 

Now, I'm not saying Elite Pharmaceuticals will n ever rise again. In fact, I specifically said the stock was entering a long-term rally phase when I explored it back in August. I'm just saying the potential pullback from here is a little more than the average investor may want to ride out. Once we bleed off some of this overbought pressure, then we can start wading back in again. That could be somewhere around the $0.10 area, where ELTP had to regroup late last week and early this week, and where the 20-day and/or the 50-day moving average lines will be in a couple of days when they could be tested.

For more trading ideas and insights like this one, sign up for the free SmallCap Network daily newsletter. It's chock full of stock picks, market calls, and more. Subscribe today.

5 Best Managed Healthcare Stocks To Watch For 2016

5 Best Managed Healthcare Stocks To Watch For 2016: Allscripts Healthcare Solutions Inc.(MDRX)

Allscripts Healthcare Solutions, Inc. provides clinical, financial, connectivity, and information solutions and related professional services to hospitals, physicians, and post-acute organizations primarily in the United States and Canada. The company?s integrated clinical software applications include acute care electronic health records, clinical and practice management solutions, revenue cycle management software, clearinghouse services, stand-alone electronic prescribing, and document imaging solutions, as well as various solutions for home care, hospice, skilled nursing, and other post-acute organizations. It also provides electronic medical records software; practice management software; electronic claims administration services; related installation and training services; hosting services for its software and outsourced solutions; and information technology outsourcing services. In addition, the company also resells related hardware products. Allscripts Healthcare S olutions, Inc. is headquartered in Chicago, Illinois.

Advisors' Opinion:

• [By George Putnam]

  After a large acquisition, made in 2010, didn't work out as planned, Allscripts Healthcare Solutions (MDRX) put itself up for sale in early 2012. This created concern among its clients, and potential clients, and eventually led to the replacement of its long-time CEO in December 2012.

• [By Ben Levisohn]

  Which might help explain why Quality Systems has dropped 0.1% to $17.98 today, even as Allscripts Healthcare Solutions (MDRX) has gained 1.7% to $16.15 and Cerner (CERN) has risen 3.4% to $55.42.

• [By Selena Maranjian]

  Other companies didn't do as well last year, but could see their fortunes change in the coming years. Allscripts Healthcare Solutions (NASDAQ: ! MDRX  ) , which delivers electronic health records (EHR) products and services, slid 20%. The company has been lagging its peers, it was a poor performer in 2012, and its latest earnings report wasn't too impressive. On the plus side, some of its insiders have been buying shares.

• [By Keith Speights]

  Cerner's recent stock performance trounces that of other publicly traded companies, including Allscripts (NASDAQ: MDRX  ) , Greenway Medical (NYSE: GWAY  ) , and Quality Systems (NASDAQ: QSII  ) . Only athenahealth (NASDAQ: ATHN  ) gives Cerner a run for its money over the past year.

source from Top Stocks For 2015:http://www.topstocksblog.com/5-best-managed-healthcare-stocks-to-watch-for-2016.html

Top Logistics Companies To Invest In Right Now

Top Logistics Companies To Invest In Right Now: Medidata Solutions Inc.(MDSO)

Medidata Solutions, Inc. provides software-as-a-service based clinical development solutions for life science organizations worldwide. Its solutions comprise software and services that allow customers to increase the value of their development programs by designing, planning, and managing key aspects of the clinical trial process, including study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding, clinical business analytics, and data flow and interoperability. The company primarily offers Medidata Rave, a comprehensive platform for capturing and managing clinical data. It also provides Medidata CTMS, a clinical trial management solution that streamlines operational workflows; Medidata Designer, a protocol development tool that enhances the efficiency of clinical trial start-up; Medidata Insights, a busi ness analytics platform; and Medidata Balance, a randomization and trial supply management solution, which streamlines the process of developing, building, and implementing subject allocation plans. In addition, the company offers Medidata Grants Manager, an application to benchmark the investigator budgets against industry data; Medidata contract research organization (CRO) Contractor, an analytical tool for CRO outsourcing, budgeting, and negotiation; and iMedidata, a hosted portal application that allows investigative sites and sponsor study teams to start trial activities. Further, it provides hosting, support, and professional services. The company serves pharmaceutical, biotechnology, and medical device companies; academic institutions; and CROs and other entities engaged in clinical trials through a direct sales force; and through relationships with CROs and other strategic partners. The company was founded in 1999 and is headquartered in! New York, New York.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Medidata Solutions (NASDAQ: MDSO) were 27.49 percent to $38.21 after the company reported downbeat quarterly results.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-logistics-companies-to-invest-in-right-now-2.html

Best Promising Companies For 2016

Best Promising Companies For 2016: Guided Therapeutics Inc (GTHP)

Guided Therapeutics, Inc., incorporated on October 27, 1992, is a medical technology company focused on developing medical devices. The Company's primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. Its technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix.

The Company's product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that preced e the development of visual lesions. The product is expected to incorporate a single-use, disposable calibration and alignment component.

The Company competes with Qiagen, MediSpectra, Inc., Merck & Co., Inc., and GlaxoSmithKline PLC.

Advisors' Opinion:

• [By CRWE]

  Today, GTHP remains (0.00%) +0.000 at $.710 with 44,700 shares in play thus far (ref. google finance Delayed: 11:42AM EDT August 21, 2013).

  Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.

  Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva® devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $9! 44,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company's esophageal cancer detection technology back in house.

• [By CRWE]

  Last Friday, GTHP had shed (-2.16%) down -0.015 at $.679 with 39,538 shares in play at the close (ref. google finance August 23, 2013 – Close).

  Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.

  Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva® devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company's esophageal cancer detection technology back in house.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-promising-companies-for-2016.html

Hot New Companies To Own In Right Now

Hot New Companies To Own In Right Now: Extreme Biodiesel Inc (XTRM)

Extreme Biodiesel Inc., formerly Book Merge Technology, Inc., incorporated on February 28, 2008, is engaged in manufacturing of home biodiesel processors. The Company focuses to produce alternative fuel. The Company has a bio diesel refinery and factory for refining diesel oil and manufacturing bio diesel processors. On October 11, 2010, the Company acquired a 51% interest in EGT. on October 11, 2010, the reverse acquisition was effected. On March 31, 2011, the Company completed the acquisition of EGT.

The Company's products include standard extractor, extreme extractor, extreme mini-refinery, extreme purification system, titration kit, dispensing pump with meter and oil collection pump. The standard extractor is a biodiesel processor, which requires a water-wash process to purify the biodiesel. Extreme extractor is a waterless purification system. The Mini Refinery is the waterless system, which can make 600 gallons of quality biodiesel per day.

Advisors' Opinion:

• [By Peter Graham]

  Small cap resource or green stocks Paradigm Resource Management Corp (OTCMKTS: PRDC), Extreme Biodiesel Inc (OTCMKTS: XTRM) and Pan Global Corp (OTCMKTS: PGLO) have all been getting some attention lately thanks in part to a few paid stock promotions. However, two of these small cap appear to be the subject of minimal paid promotion activity, but even a small paid promotion or investor relations campaign can increase a stock's volatility. So do these three small cap resource or green stocks have what it takes to deliver some Christmas cheer for investors and traders alike? Here is a quick reality check:

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-new-companies-to-own-in-right-now-4.html